文献速递淋巴瘤

BH3模拟物类药物克服ALK阳性间变性大细胞淋巴瘤微环境诱导的克唑替尼耐药

BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma.
PubMed 文献 · Blood Adv · 2025-01-01

研究在批量和单细胞水平转录层面解析了克唑替尼存在下ALK阳性间变性大细胞淋巴瘤(ALK+ ALCL)与基质细胞的双向相互作用,发现微环境提供促生存信号导致克唑替尼持留。持留细胞BCL2表达升高、凋亡相关通路下调,体外预测配体-受体相互作用支持基质细胞参与ALCL发病。克唑替尼联合BH3模拟物对反凋亡靶点的药理学和遗传学消融显示显著协同效应,克服基质介导的保护,支持在含克唑替尼方案中评估BCL2靶向治疗。

要点

  • 微环境提供促生存信号,导致ALK+ ALCL对克唑替尼持留。
  • 克唑替尼持留的ALK+ ALCL细胞BCL2表达升高、凋亡通路下调。
  • BCL2/BCL-XL靶向与克唑替尼暴露在ALK+ ALCL中呈合成致死。

核心结论

  • BCL2/BCL-XL靶向与克唑替尼暴露在ALK+ ALCL中呈合成致死,代表淋巴瘤细胞面对克唑替尼时内在和外在介导的可靶向脆弱点。
  • 数据支持在ALK+ ALCL患者管理的含克唑替尼方案中评估BCL2靶向。

研究设计与样本

  • 研究在批量和单细胞水平对克唑替尼存在下ALK+ ALCL与基质细胞的双向相互作用进行转录层面解析。
  • 研究通过计算机预测肿瘤细胞与基质细胞间的配体-受体相互作用。
  • 研究探索克唑替尼联合BH3模拟物的效果,并对反凋亡靶点进行药理学和遗传学消融。

主要发现

  • 微环境提供促生存信号,导致ALK+ ALCL对克唑替尼持留。
  • 克唑替尼持留的ALK+ ALCL细胞中BCL2表达升高、凋亡相关通路下调。
  • 计算机预测的配体-受体相互作用支持肿瘤细胞与基质细胞参与ALCL发病,主要参与黏附/膜转运、触发受体及促进淋巴瘤细胞活化和微环境刺激。
  • 对反凋亡靶点的药理学和遗传学消融与克唑替尼显示显著协同效应,克服基质介导的淋巴瘤细胞药物保护。

临床怎么用

  • 作者认为数据支持在ALK+ ALCL患者管理的含克唑替尼方案中评估BCL2靶向。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Resistance to first-line chemotherapies and crizotinib in anaplastic large cell lymphoma (ALCL) represents a significant challenge, often leading to a dismal outcome. Despite recent advancements, the dissection of the intrinsic and extrinsic molecular alterations underlying crizotinib resistance in ALCL is still poorly understood. Here, we transcriptionally unraveled the bidirectional interplay between anaplastic lymphoma kinase (ALK)-driven ALCL (ALK+ ALCL) and stromal cells in the presence of crizotinib at bulk and single-cell levels and identified that the microenvironment provides prosurvival signals leading to crizotinib persistence in ALK+ ALCL. We detected increased B-cell lymphoma 2 (BCL2) expression and downregulation of pathways related to apoptosis in crizotinib-persister ALK+ ALCL cells. Furthermore, we predicted in silico the ligand-receptor interactions between tumoral and stromal cells, supporting their contribution to ALCL pathogenesis mainly participating in the adhesion/membrane transport, triggering receptors, and promoting activation and microenvironment stimulation in lymphoma cells. Finally, we explored the effect of crizotinib in combination with BH3 mimetics. Pharmacologic and genetic ablation of anti-apoptotic targets displayed a significant synergistic effect with crizotinib, overcoming the stroma-mediated protection of lymphoma cells on drug treatment. Thus, BCL2/B-cell lymphoma-extra large (BCL-XL) targeting is synthetic lethal with crizotinib exposure in ALK+ ALCL and represents an intrinsic- and extrinsic-mediated targetable vulnerability in lymphoma cells challenged with crizotinib. Our data support the evaluation of BCL2 targeting in crizotinib-based regimens in the management of patients with ALK+ ALCL.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Pignataro C, Zoppoli P, Cappelli LV, et al. BH3 mimetic drugs overcome the microenvironment-induced resistance to crizotinib in ALK+ anaplastic large cell lymphoma. Blood Adv. 2025. PMID: 40601898. doi:10.1182/bloodadvances.2024015322

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。